Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

REMD Biotherapeutics

Status and phase: Completed; Phase 2; Phase 1

Conditions: Diabetes; Type 2 Diabetes Mellitus

Treatments: Biological: REMD-477

Study type: Interventional

Funder types: Industry

Identifiers

NCT02455011

R477-201

Details and patient eligibility

About

This is a randomized, placebo-controlled, double-blind, dose escalation study to evaluate safety, tolerability, PK and PD of single and repeated SC doses of REMD-477 in Type 2 diabetic subjects. The study will be conducted at multiple sites in the United States and will enroll approximately 102 subjects with Type 2 diabetes who are either treatment-naïve, controlled with diet and exercise or treated with oral antidiabetic medications.

Full description

The study will consist of three parts: Part A - Dose Escalation, Part B - Adaptive Dose Cohort, and Part C - REMD-477 in Combination with Metformin. Part A includes 5 cohorts that will be enrolled and dosed sequentially at escalating doses. Each cohort will consist of 12 subjects randomized in a 3:1 (active: placebo) fashion. Part B includes a single dose cohort that will enroll 12 subjects (9 on active treatment and 3 on placebo) with dose level and frequency determined by a Dose Level Review Meeting (DLRM)Committee. Part C includes 2 cohorts of T2DM patients currently treated with metformin alone, and each cohort will consist of 15 subjects (10 on active treatment and 3 on placebo).

Enrollment: 75 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening;
• Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile, and females of child bearing potential must use two medically acceptable methods of contraception;
• Male subjects must be willing to use clinically acceptable contraception during treatment and for 2 months after the last administration of REMD-477;
• Normal or clinically-acceptable physical examination, laboratory test values, and 12-lead ECG (reporting heart rate and PR, QRS, QT, and QTcF) at screening;
• Body mass index between 23 and 40 kg/m2, inclusive, at screening;
• Diagnosed with Type 2 diabetes as defined by the current American Diabetes Association (ADA) criteria;
• Subjects in Parts A and B only: Treatment-naive, controlled with diet and exercise, or treated with oral antidiabetic medications and willing to wash-out and discontinue oral medications during the study;
• Fasting plasma glucose 126 - 270 mg/dL (7-15 mM), inclusive, at screening and at re-test on Day -1;
• Subjects in Parts A and B only: Screening HbA1c of 7.0-10 % inclusive for subjects not currently taking any oral antidiabetic medications, or 6.5-9.5% for subjects receiving acceptable oral antidiabetic medications;
• Subjects in Part C only: Screening HbA1c of 7.5-10 % inclusive for subjects on stable doses of metformin.

Exclusion criteria

• History of drug or alcohol abuse within the last 6 months or a positive illegal drug urine test result;
• History or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia;
• History or family history of pheochromocytoma;
• Known or suspected susceptibility to infectious disease (eg, taking immunosuppressive agents or has a documented inherited or acquired immunodeficiency);
• Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C antibodies (HepC Ab);
• Participation in an investigational drug or device trial within 30 days of screening or within 5 times the half-life of the investigational agent in the other clinical study, if known, whichever period is longer;
• Blood donor, or blood loss>300 mL, within 30 days of Day 1;
• Recent use (6 weeks prior to Screening) of thiazolidinediones, >half-maximal dose sulfonylurea agent therapy, or any injectable antidiabetic agents (exenatide and other injectable GLP-1 agonists, insulin and insulin analogs, etc.);
• Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness) conditions specific to diabetes that would pose additional risk to subject's safety or interfere with the study evaluation, procedures or completion;
• Lipid panel profiles of non-HDL-C (total cholesterol minus HDL-C) >219 mg/dL, LDL-C >189 mg/dL, and/or fasting triglycerides >499 mg/dL;
• Female subject is pregnant or breastfeeding.

Other inclusion and exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

75 participants in 6 patient groups, including a placebo group

REMD-477 Treatment A

Experimental group

Description:

Administered as a single and repeated SC doses in subjects with Type 2 Diabetes

Treatment:

Biological: REMD-477

Matching placebo

Placebo Comparator group

Description:

Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes

Treatment:

Biological: REMD-477

REMD-477 Treatment B

Experimental group

Description:

Administered as a single and repeated SC doses in subjects with Type 2 Diabetes

Treatment:

Biological: REMD-477

REMD-477 Treatment C

Experimental group

Description:

Administered as a single and repeated SC doses in subjects with Type 2 Diabetes

Treatment:

Biological: REMD-477

REMD-477 Treatment D

Experimental group

Description:

Administered as a single and repeated SC doses in subjects with Type 2 Diabetes

Treatment:

Biological: REMD-477

REMD-477 Treatment E

Experimental group

Description:

Administered as a single and repeated SC doses in subjects with Type 2 Diabetes

Treatment:

Biological: REMD-477